Drug Type Small molecule drug |
Synonyms 2-(3,4-dihydroxyphenyl)ethylamine, 3,4-Dihydroxyphenethylamine, 3-Hydroxytyramine + [9] |
Target |
Action agonists |
Mechanism DRDs agonists(Dopamine receptors agonists) |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhasePendingPhase 1 |
First Approval Date- |
Regulation- |
Molecular FormulaC8H11NO2 |
InChIKeyVYFYYTLLBUKUHU-UHFFFAOYSA-N |
CAS Registry51-61-6 |
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | Dopamine intranasal(MetP Pharma AG) |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Parkinson Disease | Phase 1 | Switzerland | - | |
| Attention Deficit Disorder With Hyperactivity | Preclinical | Switzerland | - |





